Autonomous Technologies corrects and replaces previous earnings announcement.

--(BUSINESS WIRE)--Nov. 14, 1996--

Autonomous Technologies Reports Third Quarter Results

ORLANDO, FL--Autonomous Technologies, Corporation (NASDAQ: ATCI), today announced the financial and corporate results for the third quarter and nine months ended September 30, 1996.

The Company reported that its net loss for the third quarter ended September 30, 1996, was $2,891,380, or $0.43 per share based on 6,749,950 shares outstanding compared with a loss of $1,215,159, or $0.98 per share based on 1,245,000 shares outstanding during the third quarter 1995. For the nine months ended September 30, 1996, the net loss was $6,169,297, or $1.19 per share in comparison to a loss of $3,008,953, or $1.09 reported during the same period a year ago.

Autonomous, a company in the process of product development and clinical trials, attributed the increase in net losses to the planned expansion of its clinical trials program, which entered Phase III in the U.S. in October 1996, and to the expansion of its production organization in preparation for anticipated commercialization of its products.

Autonomous presented updated clinical results from its T-PRK(R) System for laser vision correction at the recent Annual Meeting of the American Academy of Ophthalmology in Chicago. The T-PRK(R) System is bringing patients with low to moderate myopia to 20/20 uncorrected visual acuity in over 80% of the cases after six months.

According to Randy Frey, Chairman and C.E.O. of Autonomous, "We are encouraged by these strong results, and have opened a protocol for astigmatism during the quarter. We expect to open protocols for Hyperopia and LASIK early next year."

Autonomous Technologies, Corporation (ATCI) is engaged in the design and development of next generation excimer laser instruments for laser vision correction. ATCI's T-PRK(R) (Tracker-assisted Photorefractive Keratectomy) instrument combines high speed, laser radar eye tracking (LADARVision(R)) with precisely controlled narrow beam shaping technology. -0-

             AUTONOMOUS TECHNOLOGIES CORPORATION
                 (A DEVELOPMENT STAGE COMPANY)
                  STATEMENTS OF OPERATIONS
                         (UNAUDITED)

                              Three Months Ended      Nine Months Ended
                                  Sept. 30,               Sept. 30,
                              1996         1995       1996        1995

OPERATING EXPENSES:
 Clinical trials          $ 477,282      $ 80,227  $1,153,525  $425,269
 Research and
  development             1,457,410       597,871   2,661,391 1,449,052
 Selling and marketing      281,158        65,773     788,839   342,728
 General and administrative 457,242       334,125   1,196,489   608,662
 Other expenses             431,468       150,000     731,468   225,000

OPERATING LOSS            3,104,560     1,227,996   6,531,712 3,050,711

OTHER INCOME (EXPENSE):
Interest income             224,693        12,837     379,152    41,758
Interest expense            (11,513)            -     (16,737)        -

LOSS BEFORE INCOME TAXES  2,891,380     1,215,159   6,169,297 3,008,953
INCOME TAXES                      -             -           -         -

NET LOSS                 $2,891,380    $1,215,159  $6,169,297 $3,008,953

LOSS PER SHARE:
 Net loss per share      $    (0.43)   $    (0.98) $   (1.19) $   (1.09)

Weighted average common
 and common equivalent
 shares used in
 computing net
 loss per share           6,749,950     1,245,000   5,164,668  2,770,900



                                      Sept. 30,        Dec. 31
                                         1996            1995
Selected Balance Sheet Information:
Cash and investments                $ 14,670,944    $  492,326
Total assets                        $ 16,224,470    $  799,493
Stockholder's equity (deficit)      $ 14,228,201    $(159,616)

CONTACT: Autonomous Technologies

Roslyn Palmiere

Investor Relations

[phone]

or

Lippert Heilshorn & Associates, Inc.

Keith Lippert

[phone]